Free Daily Biotech Industry Newsletter
Get the latest on Biotech & Pharma Deals, Clinical Trials, FDA Decisions, and Key Regulatory Issues sent straight to your Inbox. Join over 150,000 biotech professionals who subscribe to FierceBiotech for FREE!
Shares of BioSante ($BPAX) shot up more than 20% this morning after the developer heralded data showing improved survival rates in an early trial of GVAX for pancreatic cancer. The data is from a trial that recruited 30 patients. Story
| Wednesday, January 28, 2015 | 11am ET / 8am PT | Sponsored by: Catalent
BASF SE expert Andreas Gryczke will present fundamental understanding of Role of Polymers using hot melt extrusion technology and Catalent's expert Dr. Sampada B Upadhye will present unique approach to formulation development and strategy for scale-up. Learn How BASF & Catalent can Expedite and Resolve your Challenges with development and manufacturing.
FierceBiotech monitors biotech & pharma deals, FDA decisions, clinical trials, and more. Join more than 150,000 biotech industry leaders who subscribe to our free daily email. Click here to get your free weekly email briefing today!